We Doc Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.99 M
- Company Age 26 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
About We Doc Pharmaceuticals
We Doc Pharmaceuticals Private Limited (WDPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 October 1998 and has a history of 26 years and three months. Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.99 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Kumar and Nagendra Sinha serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233DL1998PTC096832
-
Company No.
096832
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Oct 1998
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at We Doc Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Kumar
|
Director | 27-Oct-1998 | Current |
|
Nagendra Sinha
|
Director | 27-Oct-1998 | Current |
Financial Performance of We Doc Pharmaceuticals.
We Doc Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of We Doc Pharmaceuticals?
In 2017, We Doc Pharmaceuticals had a promoter holding of 48.78% and a public holding of 51.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Shanti Niketan Buildtech Private LimitedManoj Kumar and Nagendra Sinha are mutual person
-
Rani Promoter Pvt LtdNagendra Sinha is a mutual person
-
Educity Pedagogy Private LimitedManoj Kumar and Nagendra Sinha are mutual person
-
Bsc Publishing Company Private LimitedManoj Kumar is a mutual person
-
Bsc Academy Private LimitedManoj Kumar is a mutual person
-
Bsc Correspondence Course Private LimitedManoj Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at We Doc Pharmaceuticals?
Unlock and access historical data on people associated with We Doc Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of We Doc Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped We Doc Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.